Connetics Files Suit Over Agis ANDA
The lawsuit asks that the ANDA not be considered until after the Connetics’ patents for the drug expire in 2016.
The suit says that “the defendant’s ANDA included a certification of the Act of Defendant’s purported opinion that the ‘920 patent is invalid, unenforceable, or not infringed by the submission of the Defendant’s ANDA.”
According to the complaint...
To view the full article, register now.